Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold executed sales of common stock on January 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 13, 2025, Derek J Maetzold, the President and CEO of Castle Biosciences, Inc. (CSTL), sold shares of common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Maetzold sold shares directly and indirectly through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• The sales occurred at prices ranging from $27.15 to $29.48 per share.
• Following the transactions, Maetzold directly owns 80,818 shares and indirectly owns shares through several trusts.
• The trusts include DJM Grantor Retained Annuity Trust No. 5 (122,866 shares) and DJM Grantor Retained Annuity Trust No. 6 (26,134 shares).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to insider trading. The sentiment is neutral as it simply reports transactions.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could potentially influence investor sentiment, although the existence of a pre-arranged trading plan mitigates concerns about opportunistic trading.

Key Dates